arrow
M

Mike Dennis

The Christie NHS Foundation Trust
H指数:23
被引数:2,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML.

联合中剂量阿糖胞苷和吉妥单抗奥佐米星与诱导化疗在FLT3突变急性髓系白血病中的安全性和有效性。

2025-10-030
OAAI
Induction chemotherapy and molecular MRD influence outcomes in KMT2A rearranged AML

诱导化疗和分子MRD影响KMT2A重排AML的结局

Blood
IF23.1
2025-08-080
PRE
A revised prognostic model for patients with acute myeloid leukemia and first relapse

针对急性髓系白血病首次复发的修订型预后模型

2025-05-260
OA
Predictors of Successful Allogeneic Stem Cell Donor Collection

异基因干细胞供者采集成功的预测因素

BLOOD
IF23.1
2024-11-050
PRE
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
2024-10-250
OAAI
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
2023-08-1114
OAAI
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
LEUKEMIA
IF13.4
2023-08-0920
OAAI
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation MSC-FFM-Outcome Report of 92 Patients
CELLS
IF5.2
2019-12-0538
OAAI